63

New therapies involving T lymphocytes are playing an increasingly important role in the management of refractory B-cell non-Hodgkin lymphoma (B-NHL), with chimeric antigen receptor T cells (CAR-T cells) available to patients as early as for second-line treatment in some cases. However, these treatments are associated with significant organizational challenges, as well as failure rates in more than half of cases. Bispecific antibodies therefore complement the therapeutic armory for B-NHL. Encouraging response rates are gradually extending their indications to the various types of B-NHL, offering a new option with the advantage of immediate availability. In this article, we summarize the current indications and recent advances of bispecific antibodies in B-NHL.